1. Home
  2. FGEN
  3. FGEN News

Latest FibroGen Inc (FGEN) News on January 19, 2025

FGEN

MT Newswires

a month ago

FibroGen Names David DeLucia CFO

FibroGen Appoints David DeLucia as Chief Financial Officer
FGEN

GlobeNewswire

a month ago

FibroGen Appoints David DeLucia as Chief Financial Officer

FibroGen Third Quarter 2024 Earnings: Beats Expectations
FGEN

Simply Wall St.

2 months ago

FibroGen Third Quarter 2024 Earnings: Beats Expectations

FGEN

Thomson Reuters StreetEvents

2 months ago

Q3 2024 FibroGen Inc Earnings Call

FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions
FGEN

GuruFocus.com

2 months ago

FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions

FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates
FGEN

Zacks

2 months ago

FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates

FGEN

Associated Press Finance

2 months ago

FibroGen: Q3 Earnings Snapshot

FibroGen Reports Third Quarter 2024 Financial Results
FGEN

GlobeNewswire

2 months ago

FibroGen Reports Third Quarter 2024 Financial Results

FibroGen to Report Third Quarter 2024 Financial Results
FGEN

GlobeNewswire

2 months ago

FibroGen to Report Third Quarter 2024 Financial Results

FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts
FGEN

GuruFocus.com

3 months ago

FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts

Duchenne muscular dystrophy: major trials and events to watch in 2023
FGEN

Clinical Trials Arena

4 months ago

Duchenne muscular dystrophy: major trials and events to watch in 2023

FGEN

MT Newswires

4 months ago

FibroGen Terminates CFO Juan Graham, Chief Medical Officer Deyaa Adib

FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
FGEN

GlobeNewswire

4 months ago

FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

FibroGen, Inc. (NASDAQ:FGEN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
FGEN

Simply Wall St.

5 months ago

FibroGen, Inc. (NASDAQ:FGEN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates
FGEN

Zacks

5 months ago

FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates

FGEN

Associated Press Finance

5 months ago

FibroGen: Q2 Earnings Snapshot

FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update
FGEN

GlobeNewswire

5 months ago

FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update

FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials
FGEN

Pharmaceutical Technology

6 months ago

FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials

Vertex’s pain drug gets speedy FDA review; Keytruda hits a sales milestone
FGEN

BioPharma Dive

6 months ago

Vertex’s pain drug gets speedy FDA review; Keytruda hits a sales milestone

FibroGen to Report Second Quarter 2024 Financial Results
FGEN

GlobeNewswire

6 months ago

FibroGen to Report Second Quarter 2024 Financial Results

FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update
FGEN

GlobeNewswire

6 months ago

FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update

FibroGen, Inc. (NASDAQ:FGEN) is a favorite amongst institutional investors who own 54%
FGEN

Simply Wall St.

6 months ago

FibroGen, Inc. (NASDAQ:FGEN) is a favorite amongst institutional investors who own 54%

Favourable Signals For FibroGen: Numerous Insiders Acquired Stock
FGEN

Simply Wall St.

7 months ago

Favourable Signals For FibroGen: Numerous Insiders Acquired Stock

FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024
FGEN

GlobeNewswire

7 months ago

FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024

FGEN

MT Newswires

7 months ago

FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
FGEN

GlobeNewswire

7 months ago

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
FGEN

GlobeNewswire

7 months ago

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference
FGEN

GlobeNewswire

8 months ago

FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting
FGEN

GlobeNewswire

8 months ago

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting

FibroGen First Quarter 2024 Earnings: Beats Expectations
FGEN

Simply Wall St.

8 months ago

FibroGen First Quarter 2024 Earnings: Beats Expectations

FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript
FGEN

Insider Monkey

8 months ago

FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript

FGEN

Thomson Reuters StreetEvents

8 months ago

Q1 2024 FibroGen Inc Earnings Call

FGEN

MT Newswires

8 months ago

Top Premarket Gainers

FibroGen to Participate in Upcoming Investor Conferences
FGEN

GlobeNewswire

8 months ago

FibroGen to Participate in Upcoming Investor Conferences

FGEN

GuruFocus.com

8 months ago

FibroGen Inc (FGEN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...

FGEN

Associated Press Finance

8 months ago

FibroGen: Q1 Earnings Snapshot

FibroGen Reports First Quarter 2024 Financial Results
FGEN

GlobeNewswire

8 months ago

FibroGen Reports First Quarter 2024 Financial Results

FibroGen to Report First Quarter 2024 Financial Results
FGEN

GlobeNewswire

9 months ago

FibroGen to Report First Quarter 2024 Financial Results

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
FGEN

GlobeNewswire

9 months ago

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting

Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
FGEN

Zacks

9 months ago

Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies

Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
FGEN

Zacks

9 months ago

Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study

Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
FGEN

Zacks

9 months ago

Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why

RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
FGEN

Zacks

9 months ago

RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up

Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
FGEN

Zacks

9 months ago

Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?

Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
FGEN

Zacks

9 months ago

Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study

Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
FGEN

Zacks

9 months ago

Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why

Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
FGEN

Zacks

10 months ago

Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
FGEN

GlobeNewswire

10 months ago

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
FGEN

Zacks

10 months ago

Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why

Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
FGEN

Zacks

10 months ago

Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
FGEN

GlobeNewswire

10 months ago

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals
FGEN

Zacks

10 months ago

Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals

Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data
FGEN

Zacks

10 months ago

Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data

Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA
FGEN

Zacks

10 months ago

Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA

Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag
FGEN

Zacks

10 months ago

Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag

Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails
FGEN

Zacks

10 months ago

Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
FGEN

GlobeNewswire

10 months ago

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Novo Nordisk's (NVO) Wegovy Gets FDA Nod to Reduce Heart Risk
FGEN

Zacks

10 months ago

Novo Nordisk's (NVO) Wegovy Gets FDA Nod to Reduce Heart Risk

FibroGen, Inc. (NASDAQ:FGEN) Q4 2023 Earnings Call Transcript
FGEN

Insider Monkey

a year ago

FibroGen, Inc. (NASDAQ:FGEN) Q4 2023 Earnings Call Transcript

US$1.25: That's What Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Is Worth After Its Latest Results
FGEN

Simply Wall St.

a year ago

US$1.25: That's What Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Is Worth After Its Latest Results

FibroGen Full Year 2023 Earnings: Misses Expectations
FGEN

Simply Wall St.

a year ago

FibroGen Full Year 2023 Earnings: Misses Expectations

FGEN

Thomson Reuters StreetEvents

a year ago

Q4 2023 FibroGen Inc Earnings Call

FGEN

Associated Press Finance

a year ago

FibroGen: Q4 Earnings Snapshot

FibroGen Inc (FGEN) Reports Modest Revenue Growth and Reduced Net Loss in FY 2023
FGEN

GuruFocus.com

a year ago

FibroGen Inc (FGEN) Reports Modest Revenue Growth and Reduced Net Loss in FY 2023

FGEN

Reuters

a year ago

UPDATE 1-FibroGen regains rights to anemia drug from AstraZeneca

FGEN

Reuters

a year ago

FibroGen regains rights to anemia drug from AstraZeneca

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
FGEN

GlobeNewswire

a year ago

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
FGEN

GlobeNewswire

a year ago

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
FGEN

GlobeNewswire

a year ago

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024
FGEN

GlobeNewswire

a year ago

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

/C O R R E C T I O N -- Nutex Health, Inc./
FGEN

PR Newswire

a year ago

/C O R R E C T I O N -- Nutex Health, Inc./

FibroGen, Inc. (NASDAQ:FGEN) institutional owners may be pleased with recent gains after 96% loss over the past year
FGEN

Simply Wall St.

a year ago

FibroGen, Inc. (NASDAQ:FGEN) institutional owners may be pleased with recent gains after 96% loss over the past year

SYLA Technologies Announces FY2024 Financial Guidance and Upward Revision of FY2023 Dividend Forecast
FGEN

GlobeNewswire

a year ago

SYLA Technologies Announces FY2024 Financial Guidance and Upward Revision of FY2023 Dividend Forecast

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer
FGEN

GlobeNewswire

a year ago

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

Why Eagle Bancorp Montana, Inc. (EBMT) is a Top Dividend Stock for Your Portfolio
FGEN

Zacks

a year ago

Why Eagle Bancorp Montana, Inc. (EBMT) is a Top Dividend Stock for Your Portfolio

Should You Investigate Mama's Creations, Inc. (NASDAQ:MAMA) At US$4.70?
FGEN

Simply Wall St.

a year ago

Should You Investigate Mama's Creations, Inc. (NASDAQ:MAMA) At US$4.70?

Radcom (RDCM) Surges 5.4%: Is This an Indication of Further Gains?
FGEN

Zacks

a year ago

Radcom (RDCM) Surges 5.4%: Is This an Indication of Further Gains?

Cambium Networks Corporation Announces Preliminary Fourth Quarter 2023 Revenues, Reporting Date and CFO Transition
FGEN

PR Newswire

a year ago

Cambium Networks Corporation Announces Preliminary Fourth Quarter 2023 Revenues, Reporting Date and CFO Transition

Cue Biopharma (NASDAQ:CUE) investors are sitting on a loss of 80% if they invested three years ago
FGEN

Simply Wall St.

a year ago

Cue Biopharma (NASDAQ:CUE) investors are sitting on a loss of 80% if they invested three years ago

D-Wave Becomes First Full-Stack Quantum Provider to Achieve SOC 2 Type 2 Compliance
FGEN

NewMediaWire

a year ago

D-Wave Becomes First Full-Stack Quantum Provider to Achieve SOC 2 Type 2 Compliance

FGEN

Business Wire

a year ago

Superior Appoints Deven Petito to its Board of Directors

FGEN

Investing.com

a year ago

Shoe retailer Genesco cuts full-year earnings forecast, shares plunge premarket

Be Wary Of Latham Group (NASDAQ:SWIM) And Its Returns On Capital
FGEN

Simply Wall St.

a year ago

Be Wary Of Latham Group (NASDAQ:SWIM) And Its Returns On Capital

Health Care Roundup: Market Talk
FGEN

The Wall Street Journal

a year ago

Health Care Roundup: Market Talk

Novo Nordisk, The Weight-Loss Kingpin, Breaks Out After Inking Two New Deals In Obesity
FGEN

Investor's Business Daily

a year ago

Novo Nordisk, The Weight-Loss Kingpin, Breaks Out After Inking Two New Deals In Obesity

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones
FGEN

GlobeNewswire

a year ago

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

Relmada Therapeutics Provides Corporate Update
FGEN

PR Newswire

a year ago

Relmada Therapeutics Provides Corporate Update

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
FGEN

Business Wire

a year ago

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

Sky Harbour Announces Incoming Chief Operating Officer, New Manufacturing Leadership, and an Update on Construction Budget at Dallas-Addison Airport
FGEN

Business Wire

a year ago

Sky Harbour Announces Incoming Chief Operating Officer, New Manufacturing Leadership, and an Update on Construction Budget at Dallas-Addison Airport

Parke Bancorp Inc's Dividend Analysis
FGEN

GuruFocus.com

a year ago

Parke Bancorp Inc's Dividend Analysis

Alphavest Acquisition Corp Announces Adjournment of Extraordinary General Meeting of Shareholders
FGEN

GlobeNewswire

a year ago

Alphavest Acquisition Corp Announces Adjournment of Extraordinary General Meeting of Shareholders

Innate Pharma Announces Leadership Change
FGEN

Business Wire

a year ago

Innate Pharma Announces Leadership Change

Turtle Beach’s Groundbreaking & Critically Acclaimed Designed for Xbox Stealth Ultra Wireless Controller Launches Globally
FGEN

Business Wire

a year ago

Turtle Beach’s Groundbreaking & Critically Acclaimed Designed for Xbox Stealth Ultra Wireless Controller Launches Globally

FGEN

PR Newswire

a year ago

JOHN HANCOCK CLOSED-END FUNDS ANNOUNCE RENEWAL OF SHARE REPURCHASE PLANS

Why Fast-paced Mover Ocwen (OCN) Is a Great Choice for Value Investors
FGEN

Zacks

a year ago

Why Fast-paced Mover Ocwen (OCN) Is a Great Choice for Value Investors

WESTERN COPPER AND GOLD ANNOUNCES COMPLETION OF FURTHER INVESTMENT AND ENTRY INTO A NEW INVESTOR RIGHTS AGREEMENT WITH RIO TINTO
FGEN

CNW Group

a year ago

WESTERN COPPER AND GOLD ANNOUNCES COMPLETION OF FURTHER INVESTMENT AND ENTRY INTO A NEW INVESTOR RIGHTS AGREEMENT WITH RIO TINTO

Hamilton Beach Brands Holding (NYSE:HBB) investors are sitting on a loss of 18% if they invested five years ago
FGEN

Simply Wall St.

a year ago

Hamilton Beach Brands Holding (NYSE:HBB) investors are sitting on a loss of 18% if they invested five years ago

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting
FGEN

GlobeNewswire

a year ago

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

Vanda (VNDA) Rises as FDA Accepts NDA for Gastroparesis Drug
FGEN

Zacks

a year ago

Vanda (VNDA) Rises as FDA Accepts NDA for Gastroparesis Drug

FGEN

Business Wire

a year ago

M-tron Industries, Inc. to Present at Sidoti Virtual Investor Conference December 6-7

Share on Social Networks: